Your browser doesn't support javascript.
loading
Integrin αvß6-TGFß-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati, Archis; Kumar, Sushil; Jiang, Peng; Pyrdol, Jason; Zou, Angela E; Godicelj, Anze; Mathewson, Nathan D; Cartwright, Adam N R; Cejas, Paloma; Brown, Myles; Giobbie-Hurder, Anita; Dillon, Deborah; Agudo, Judith; Mittendorf, Elizabeth A; Liu, X Shirley; Wucherpfennig, Kai W.
Afiliação
  • Bagati A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02215, USA.
  • Kumar S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Jiang P; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Pyrdol J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Zou AE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Godicelj A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Mathewson ND; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Cartwright ANR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Giobbie-Hurder A; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Dillon D; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
  • Agudo J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02215, USA; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Liu XS; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Room 736, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Department of Neurology, Brigham & Women's Hospital, Harvard Medical School,
Cancer Cell ; 39(1): 54-67.e9, 2021 01 11.
Article em En | MEDLINE | ID: mdl-33385331
Cancer immunotherapy shows limited efficacy against many solid tumors that originate from epithelial tissues, including triple-negative breast cancer (TNBC). We identify the SOX4 transcription factor as an important resistance mechanism to T cell-mediated cytotoxicity for TNBC cells. Mechanistic studies demonstrate that inactivation of SOX4 in tumor cells increases the expression of genes in a number of innate and adaptive immune pathways important for protective tumor immunity. Expression of SOX4 is regulated by the integrin αvß6 receptor on the surface of tumor cells, which activates TGFß from a latent precursor. An integrin αvß6/8-blocking monoclonal antibody (mAb) inhibits SOX4 expression and sensitizes TNBC cells to cytotoxic T cells. This integrin mAb induces a substantial survival benefit in highly metastatic murine TNBC models poorly responsive to PD-1 blockade. Targeting of the integrin αvß6-TGFß-SOX4 pathway therefore provides therapeutic opportunities for TNBC and other highly aggressive human cancers of epithelial origin.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Integrinas / Evasão Tumoral / Fatores de Transcrição SOXC / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos / Anticorpos Monoclonais / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Integrinas / Evasão Tumoral / Fatores de Transcrição SOXC / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos / Anticorpos Monoclonais / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article